RxDoctor Payments Data

Ericka Eyas

Psychiatric/Mental Health · Elgin, ILNPI 1437827037

Payments from drug & device makers

$1,551in general payments, 2019–2025

Across 57 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$544
  • Otsuka America Pharmaceutical, Inc.$493
  • Vanda Pharmaceuticals Inc.$125
  • Neurocrine Biosciences, Inc.$99
  • Tris Pharma Inc$76
  • Lundbeck LLC$67
  • plus $147 from 6 others

What the payments were for

  • Food & beverage$1,551100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,551 in reported general payments places this provider in the 75th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$45,996
Medicare patients
158
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide15$5,285
Divalproex Sodium81$2,482
Aripiprazole63$2,092
Trazodone Hcl78$1,229
Sertraline Hcl82$1,200
Duloxetine Hcl56$1,117
Quetiapine Fumarate66$1,072
Olanzapine49$782
Lamotrigine50$574
Bupropion XlBupropion Hcl15$510
Risperidone26$427
Venlafaxine Hcl ErVenlafaxine Hcl19$414
Prazosin Hcl19$247
Lorazepam32$244
Gabapentin15$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$25$5,28515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →